Biotech Startups

Arpelos Biosciences is a seed-stage biotech company developing multivalent targeted therapeutics aimed at high potency and selectivity, drawing on compute, immunology, and protein engineering. It is based in Kendall Square (Cambridge, Massachusetts).

2 investors

ArrePath is a biotechnology company that applies AI/ML to drug discovery and development. The company leverages computational platforms and data science to accelerate the identification and advancement of new therapeutic candidates across multiple disease areas.

2 investors

Arrivo Bio develops novel, disease-modifying medicines targeting the root cause of hard-to-treat diseases for which few effective treatment options exist. The company partners with Mayo Clinic and Daiichi Sankyo to advance first-of-its-kind therapies.

2 investors

Arrowsmith Genetics is a preclinical-stage drug discovery company developing therapeutics from genetic research conducted at UBC and BC Cancer. The company was founded to advance potential treatments derived from 20+ years of scientific insights in cancer and genetic biology.

2 investors

Arthrosi Therapeutics is a clinical-stage biopharmaceutical company developing treatments for gout, an inflammatory arthritis condition. Its lead molecule, AR882, is a urate-lowering agent aimed at reducing uric acid, tophi, and gout flares.

2 investors

Artica Therapeutics develops orally bioavailable small molecule inhibitors that use covalent chemistry to achieve antibody-like efficacy, positioned as an "antibody-in-a-pill" approach. The company targets severe autoimmune and inflammatory disorders for patients with immune-mediated conditions.

2 investors

Arvada Therapeutics is a biotechnology company focused on drug development for rare and degenerative diseases, working across preclinical research and clinical stages. Its work spans biologics development, including areas such as cardiovascular and immunology-related programs.

2 investors

Asclepii makes Poseidon, an FDA-cleared nanosilver hydrogel wound dressing that maintains a moist wound environment and blocks microbes for topical wound management. It is used by clinicians such as podiatrists and nurses for chronic and everyday wound care.

2 investors

Assembly Bio is a biopharmaceutical company developing novel therapeutic candidates for viral and liver diseases, including programs targeting herpesviruses, hepatitis delta virus, hepatitis B virus, and cholestatic liver diseases.

2 investors

Astonishing Labs partners with university lab scientists to commercialize early-stage biological research and build biotech platform companies aimed at developing new therapies. It focuses on funding research that departs from established scientific conventions, working at the earliest stage of the innovation life cycle.

2 investors

Astraea provides clinical trial automation software for pharmaceutical sponsors that uses AI to automate post-protocol tasks including statistical analysis plans, case report forms, datasets, regulatory documentation, and FDA submissions. The platform is deployed within the sponsor's own environment to maintain data security and compliance across oncology, rare disease, and medical devices.

2 investors

Astraveus develops the Lakhesys Benchtop Cell Factory, a microfluidic-based bioprocessing platform for scaling cell and gene therapy manufacturing with improved quality and cost efficiency. The company serves biotech and pharma organizations working on cell therapy manufacturing and commercialization.

2 investors

bioMérieux develops in vitro diagnostic systems and molecular testing panels for pathogen detection in clinical, food safety, and pharmaceutical quality control settings. The company serves healthcare providers, laboratories, food industry, and pharmaceutical manufacturers with rapid PCR-based diagnostic solutions.

2 investors

芯宿科技 (Atantares) develops molecular chips using semiconductor technologies such as integrated circuits, CMOS and MEMS to enable high-throughput, low-cost synthesis and detection of DNA, RNA and proteins. It offers a gene synthesis platform and services including primer synthesis, gene synthesis, sequencing, cloning and mutation, strain library preparation and gene editing, along with its EcoSyn electrochemical oligonucleotide synthesizer.

2 investors

2 investors

Atlas builds a foundational model of human biology used to predict patient outcomes and run virtual clinical trials. It serves drug developers and clinical program teams seeking to improve trial success and reduce costs.

2 investors

AtlasDiscovery develops foundation models of patient drug response trained on pre-clinical and clinical data to improve drug trial design and success rates. The company serves pharmaceutical and biotech firms by predicting human drug responses and enabling drug rescue and development in the biotech industry.

2 investors

Atlas Venture is a venture capital firm that invests in life sciences and biotech companies, with a team of advisors and entrepreneurs-in-residence who are experienced leaders in drug discovery and therapeutics development.

2 investors

AtlasXomics develops spatial epigenomics tools, spanning chip fabrication, hardware, and bioinformatics, for researchers studying areas such as cancer and systems biology. The company serves scientific and clinical research customers with technology for analyzing epigenetic regulation.

2 investors

Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases that cause vision loss. The company focuses on genetic medicines for conditions with limited approved therapies, utilizing proprietary AAV technology platforms.

2 investors

Atterx develops novel pharmaceutical therapies to prevent and treat antibiotic-resistant bacterial infections using bacterial interference and conjugation technologies. The company targets multi-drug resistant infections through specialty pharmaceutical products designed for clinical development.

2 investors

Attgeno is a pharmaceutical company developing Supernitro, a therapy focused on the targeted delivery of nitric oxide to treat critically ill patients. The company works in the biotech and drug development field across specific disease areas.

2 investors

Aurealis Therapeutics is a Swiss-Finnish clinical-stage company developing multi-target bacterial gene therapies based on genetically engineered Lactococcus cremoris, using a modular platform that produces multiple human therapeutic proteins directly in diseased tissue. Its therapies target chronic wounds, cancer, and inflammatory diseases, with a lead product for diabetic foot ulcers.

2 investors

2 investors